WHO Announces Influenza Vaccine Composition for Northern Hemisphere Season: What You Need to Know

What Did WHO Recommend for the Upcoming Flu Vaccine?

The World Health Organization convenes its Global Influenza Surveillance and Response System (GISRS) experts twice annually to analyze circulating influenza strains and recommend which viruses should be included in seasonal vaccines. For the 2026–2027 northern hemisphere season, the organization has issued updated strain recommendations that reflect shifts in the dominant influenza A and B lineages detected through global surveillance networks spanning over 140 countries.

These recommendations are essential because influenza viruses mutate frequently through antigenic drift, meaning last year's vaccine may not provide adequate protection against newly dominant strains. Vaccine manufacturers rely on WHO's guidance to begin the approximately six-month production process needed to have doses ready before the onset of the flu season, typically between October and March in the northern hemisphere.

Why Do Influenza Vaccine Strains Change Every Year?

Influenza viruses are among the most rapidly evolving pathogens affecting humans. Through a process called antigenic drift, small mutations accumulate in the surface proteins hemagglutinin (HA) and neuraminidase (NA), which are the primary targets of the immune response. When these changes are significant enough, antibodies generated by previous infection or vaccination may no longer recognize the virus effectively, leaving populations vulnerable to new seasonal waves.

WHO's GISRS network, which includes WHO Collaborating Centres, National Influenza Centres, and reference laboratories, continuously monitors influenza activity worldwide. Scientists analyze thousands of virus samples each year to identify emerging variants and assess whether current vaccine strains still provide adequate protection. This ongoing surveillance forms the scientific basis for the biannual strain selection meetings held in February (for the northern hemisphere) and September (for the southern hemisphere).

How Effective Are Seasonal Flu Vaccines and Who Should Get Them?

According to WHO and the U.S. Centers for Disease Control and Prevention (CDC), seasonal influenza vaccines generally reduce the risk of flu illness by approximately 40–60% during seasons when the vaccine is well-matched to circulating viruses. Even when effectiveness is moderate, vaccination significantly reduces the risk of severe outcomes including hospitalization and death, particularly among vulnerable populations such as older adults, young children, pregnant women, and individuals with chronic medical conditions.

WHO recommends that countries prioritizing influenza vaccination should focus first on pregnant women, followed by children aged 6 months to 5 years, older adults, individuals with chronic health conditions, and healthcare workers. The organization estimates that seasonal influenza results in approximately 290,000 to 650,000 respiratory deaths annually worldwide, underscoring the critical importance of updated, well-matched vaccines in reducing the global disease burden each year.